Scientific Calendar April 2026
Can urinary flow cytometry support treatment monitoring for systemic UTI in the emergency setting?
What does a persistent, high bacterial count in follow-up urine flow cytometry most likely indicate?
Congratulations!
That's the correct answer!
Sorry! That´s not completely correct!
Please try again
Sorry! That's not the correct answer!
Please try again
Notice
Please select at least one answer
Explanation
Scientific background
Urinary tract infections (UTIs) are among the most common bacterial infections in hospitalised patients and represent a substantial cause of morbidity and mortality worldwide.1 Severe forms of UTI, including pyelonephritis and urosepsis, frequently require hospital admission and prompt antimicrobial treatment.2 UTIs are responsible for a considerable number of hospitalisations and are associated with measurable in-hospital mortality, particularly in elderly or comorbid patients.3 Early diagnosis and timely initiation of empirical antibiotic therapy are therefore essential to improve clinical outcomes and reduce the risk of complications.4
Rapid diagnostic tools play an important role in the initial evaluation of patients with suspected UTI. Fluorescence flow cytometry-based analysis of urine specimens has become an established method for the rapid detection and quantification of bacteriuria and other urinary particles, enabling clinicians to obtain preliminary diagnostic information within minutes.1,2 Instruments such as automated urine flow cytometers can support early clinical decision-making in emergency and hospital settings.3
Despite these advances, assessment of therapeutic efficacy remains challenging in the early phase of treatment. Conventional microbiological culture and antimicrobial susceptibility testing (AST) remain the reference standard for pathogen identification and resistance profiling but typically require 24–72 hours to generate definitive results.4,5 Consequently, clinicians often have limited information on treatment response during the first days of therapy, which may delay optimisation of antimicrobial regimens.6
Earlier detection of treatment response or failure could be particularly valuable in the context of antimicrobial stewardship. Timely identification of ineffective therapy may enable earlier adjustment of antibiotic treatment, while confirmation of therapeutic success could support earlier de-escalation or switching from intravenous to oral antibiotics.7,8 Given the increasing prevalence of antimicrobial resistance among uropathogens, improved methods for early monitoring of treatment efficacy are urgently needed.9
Detailed content
Clinical scenario
Patients presenting to the emergency department with symptoms of a systemic urinary tract infection (UTI) require rapid diagnostic assessment and timely treatment. Urine samples can be analysed using the UF-5000 to determine the presence of bacteriuria. Patients with confirmed bacteriuria are typically admitted to hospital and started on empiric intravenous antibiotic therapy.
The efficacy of treatment may be monitored after approximately 12 hours using follow-up flow cytometric measurements. If therapy proves effective, patients may be switched to oral antibiotics as part of antimicrobial stewardship strategies, enabling earlier hospital discharge and potential cost savings. In addition, early changes in bacterial counts may help predict treatment failure one to three days before culture results become available. These considerations raise the question of whether the UF-Series can support the monitoring of treatment efficacy in patients with systemic UTI.
Case example – non-optimal treatment response
A 79-year-old female patient with a urinary catheter presented to the emergency department with symptoms of acute, recurrent cystitis. Analysis of a urine sample using the UF-5000 revealed high bacterial counts. The identified uropathogen was Serratia marcescens.
Initial empiric treatment with Cefuroxime administered intravenously proved to be non-optimal due to resistance. The therapy was subsequently optimised by switching to intravenous Ceftriaxone, which was appropriate for combatting the pathogen. Early optimisation of treatment, initiated before final microbiological results were available, contributed to an improved patient outcome.
| Item | Unit | Reference range | 05.12.2023 09:40:10 | 02.12.2023 08:35:42 |
| Immo-Care | negative | |||
| Type of urine sample | Indwelling catheter | Disposable catheter | ||
| -Specific Gravity | 1,000 – 1,030 | 1,011 | 1,021 | |
| -Leukocytes (Urine) | /µL | negative | 500 | 500 |
| -Nitrite (Urine) | negative | + | + | |
| -pH (Urine) | 8.5 | 8.5 | ||
| -Protein (Urine) | mg/dL | negative | +– | 2+ |
| -Glucose (Urine) | mg/dL | negative | negative | negative |
| -Ketone (Urine) | mg/dL | negative | negative | negative |
| -Urobilinogen (Urine) | mg/dL | negative | normal | normal |
| -Bilirubin (Urine) | mg/dL | negative | negative | negative |
| -Erythrocytes (Urine) | /µL | negative | 50 | 250 |
| Bacteria (Urine), quantitative | /µL | < 100 | 12852 | 3509 |
| Leucocytes (Urine), quantitative | /µL | < 40 | 888 | 6504 |
| Erythrocytes (Urine), quantitative | /µL | < 28 | 61 | 249 |
| Pathol. Casts (Urine), quantitative | /µL | < 1 | 0 | 1 |
| Crystals (Urine), quantitative | /µL | < 10 | 0 | 0 |
| Urine Sediment | N/A | N/A |
UF-5000 bacteria channel scattergrams indicating a persistently high bacterial load in the patient’s urine specimens. The corresponding table lists the complete urinalysis results; figures highlighted in red reflect the ongoing infection scenario.
Case example – optimal treatment response
A 56-year-old female patient presented to the emergency department with symptoms of acute, recurrent cystitis. Analysis of a urine sample using the UF-5000 showed high bacterial counts. The identified uropathogen was Escherichia coli, confirmed through a 72-hour microbiology workflow.
Empiric intravenous therapy with Cefuroxime was initiated and resulted in an excellent clinical response. Following stabilisation, treatment was switched to oral therapy as part of an antimicrobial stewardship measure. This step supported early hospital discharge and contributed to cost savings.
| Item | Unit | Reference range | 31.05.2024 16:23:28 | 30.05.2024 12:19:43 |
| Immo-Care | negative | |||
| Type of urine sample | Mid-stream urine | Spot urine | ||
| -Specific Gravity | 1,000 – 1,030 | 1,027 | 1,018 | |
| -Leukocytes (Urine) | /µL | negative | 500 | 500 |
| -Nitrite (Urine) | negative | negative | + | |
| -pH (Urine) | 6.0 | 6.0 | ||
| -Protein (Urine) | mg/dL | negative | 1+ | 2+ |
| -Glucose (Urine) | mg/dL | negative | negative | negative |
| -Ketone (Urine) | mg/dL | negative | negative | negative |
| -Urobilinogen (Urine) | mg/dL | negative | normal | normal |
| -Bilirubin (Urine) | mg/dL | negative | negative | negative |
| -Erythrocytes (Urine) | /µL | negative | negative | 250 |
| Bacteria (Urine), quantitative | /µL | < 100 | 47 | 87317 |
| Leucocytes (Urine), quantitative | /µL | < 40 | 947 | 3728 |
| Erythrocytes (Urine), quantitative | /µL | < 28 | 12 | 65 |
| Pathol. Casts (Urine), quantitative | /µL | < 1 | 0 | 1 |
| Crystals (Urine), quantitative | /µL | < 10 | 0 | 0 |
| Urine Sediment | N/A | N/A |
UF-5000 bacteria channel scattergrams demonstrating the successful disappearance of the patient’s bacteriuria. The corresponding table lists the complete urinalysis results; figures highlighted in red reflect the subsiding infection.
Potential to improve UTI management for hospitalised patients
In addition to the above case examples, the below table highlights three examples for each of the two scenarios of optimal and non-optimal treatment response, respectively.
| #BACT (UF-5000) | Antibiotic therapy | Microbiology | ||||||
#BACT at 0h | #BACT at 12h | Ex vivo response | Initial therapy | Modification | Species | UFC/mL | Resistance pattern | Susceptibility |
| 15,208 | 662 | 4.35 | MEC | no req | EC | 107 | cefurox | sensitive |
| 63,367 | 4,996 | 7.88 | AMS | no req | EC KP | 105 | wt | sensitive |
| 28,394 | 4,437 | 15.63 | CTX | no req | CK | 107 | wt | sensitive |
| 42,539 | 19,905 | 46.79 | CTX | MEP | CF EF | 106 | AmpC | resistant |
| 77,906 | 53,203 | 68.29 | CXM | TZP | EC PM | 107 | ESBL | resistant |
| 99,999 | 87,515 | 87.52 | CXM | CXM | EC | 107 | ESBL | resistant |
The insights from this case series led to proposing the below clinical workflow for the early management and monitoring of patients presenting with symptoms of systemic urinary tract infection (UTI). Patients admitted to the emergency department undergo rapid urinalysis using fluorescence flow cytometry to detect and quantify bacteriuria. In cases of confirmed bacteriuria and clinical suspicion of systemic infection, patients are admitted to hospital and empirically treated with intravenous antibiotics.
Follow-up flow cytometric analysis is performed after approximately 12–24 hours to evaluate changes in bacterial counts and to assess treatment response. A reduction in bacteriuria may indicate effective therapy and support early optimisation of treatment, such as switching from intravenous to oral antibiotics as part of antimicrobial stewardship strategies. Conversely, persistent or increasing bacterial counts may suggest treatment failure and prompt early therapeutic adjustment before conventional culture and susceptibility testing results become available.
